The discovery of iPS cells has developed the study of regenerative medicine. Especially, the platelet from iPS cells-derived megakaryosyte is little to worry about in terms of safety. We suppose that in this way, artificial production of platelets is very near commercialization. However, the efficiency of platelet yield from a static culture is low. Therefore, in this paper was prepared the bioreactor aim of highly efficient recovery of platelets. Results of flow culture, we were able to give the load due to the flow as well as in vivo to cells. We have examined the flow culture conditions. And we were introduced into the reactor feeder cells. Finally more than three times the number of platelet production is obtained compared to stationary culture by combining the above conditions.